Search Results - "Balthasar, Joseph P."

Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development by Glassman, Patrick M., Balthasar, Joseph P.

“…Over the past few decades, monoclonal antibodies (mAbs) have become one of the most important and fastest growing classes of therapeutic molecules, with…”
Get full text

Evaluation of a Catenary PBPK Model for Predicting the In Vivo Disposition of mAbs Engineered for High-Affinity Binding to FcRn by Chen, Yang, Balthasar, Joseph P.

“…Efforts have been made to extend the biological half-life of monoclonal antibody drugs (mAbs) by increasing the affinity of mAb–neonatal Fc receptor (FcRn)…”
Get full text

Strategies to enhance monoclonal antibody uptake and distribution in solid tumors by Bordeau, Brandon M, Balthasar, Joseph P

“…Despite the significant resources dedicated to the development of monoclonal antibody (mAb) therapies for solid tumors, the clinical success, thus far, has…”
Get full text

Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies by Glassman, Patrick M., Balthasar, Joseph P.

“…Accurate prediction of the clinical pharmacokinetics of new therapeutic entities facilitates decision making during drug discovery, and increases the…”
Get full text

Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice by Garg, Amit, Balthasar, Joseph P

“…Although it is known that FcRn, the neonatal Fc-receptor, functions to protect immune gamma globulin (IgG) from elimination, the influence of FcRn on the…”
Get full text

Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies by Cao, Yanguang, Balthasar, Joseph P., Jusko, William J.

“…Minimal physiologically-based pharmacokinetic (mPBPK) models provide a sensible modeling approach when fitting only plasma (or blood) data yielding…”
Get full text

Half-Life Extension and Biodistribution Modulation of Biotherapeutics via Red Blood Cell Hitch-Hiking with Novel Anti-Band 3 Single-Domain Antibodies by Nguyen, Toan D, Bordeau, Brandon M, Zhang, Yu, Mattle, Anna G, Balthasar, Joseph P

“…Small therapeutic proteins are receiving increased interest as therapeutic drugs; however, their clinical success has been limited due to their rapid…”
Get full text

Investigation of the Influence of FcRn on the Distribution of IgG to the Brain by Garg, Amit, Balthasar, Joseph P.

“…It has been suggested that the neonatal Fc receptor (FcRn) is a primary determinant of the distribution of IgG to the brain. In the present report, 125…”
Get full text

FcRn Expression in Wildtype Mice, Transgenic Mice, and in Human Tissues by Li, Tommy, Balthasar, Joseph P

“…Quantitative real-time PCR and Western blot methods were developed to assess neonatal Fc-receptor (FcRn) mRNA and protein expression in human FcRn transgenic…”
Get full text

Application of a catenary PBPK model to predict the disposition of “catch and release” anti-PCSK9 antibodies by Glassman, Patrick M., Balthasar, Joseph P.

“…[Display omitted] The development of ‘catch and release’, or pH-sensitive, monoclonal antibodies (mAb) has become of interest to groups seeking to reduce the…”
Get full text

Assessments of antibody biodistribution by Glassman, Patrick M., Abuqayyas, Lubna, Balthasar, Joseph P.

“…Monoclonal antibody (mAb) therapeutics are in use for several disease conditions, and have generally shown excellent clinical benefit, in large part due to…”
Get full text

High-Throughput Method Development for Sensitive, Accurate, and Reproducible Quantification of Therapeutic Monoclonal Antibodies in Tissues Using Orthogonal Array Optimization and Nano Liquid Chromatography/Selected Reaction Monitoring Mass Spectrometry by Duan, Xiaotao, Abuqayyas, Lubna, Dai, Lipeng, Balthasar, Joseph P, Qu, Jun

“…Although liquid chromatography/mass spectrometry using selected reaction monitoring (LC/SRM-MS) holds great promise for targeted protein analysis,…”
Get full text

Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody by Urva, Shweta R, Yang, Victor C, Balthasar, Joseph P

“…Antibodies directed against tumor associated antigens are being increasingly used for detection and treatment of cancers; however, there is an incomplete…”
Get more information

Development and Evaluation of Competitive Inhibitors of Trastuzumab-HER2 Binding to Bypass the Binding-Site Barrier by Bordeau, Brandon M, Abuqayyas, Lubna, Nguyen, Toan D, Chen, Ping, Balthasar, Joseph P

“…Our group has developed and experimentally validated a strategy to increase antibody penetration in solid tumors through transient inhibition of…”
Get full text

Pharmacokinetic and Pharmacodynamic Considerations for the Use of Monoclonal Antibodies in the Treatment of Bacterial Infections by Wang-Lin, Shun, Balthasar, Joseph

“…Antibiotic-resistant bacterial pathogens are increasingly implicated in hospital- and community-acquired infections. Recent advances in monoclonal antibody…”
Get full text

PK/TD modeling for prediction of the effects of 8C2, an anti-topotecan mAb, on topotecan-induced toxicity in mice by Shah, Dhaval K., Balthasar, Joseph P.

“…To facilitate the development of an inverse targeting strategy, where anti-topotecan antibodies are administered to prevent systemic toxicity following…”
Get full text

Dynamic Contrast-Enhanced Magnetic Resonance Imaging for the Prediction of Monoclonal Antibody Tumor Disposition by Bordeau, Brandon M, Polli, Joseph Ryan, Schweser, Ferdinand, Grimm, Hans Peter, Richter, Wolfgang F, Balthasar, Joseph P

“…The prediction of monoclonal antibody (mAb) disposition within solid tumors for individual patients is difficult due to inter-patient variability in tumor…”
Get full text

Application of PBPK modeling to predict monoclonal antibody disposition in plasma and tissues in mouse models of human colorectal cancer by Abuqayyas, Lubna, Balthasar, Joseph P.

“…This investigation evaluated the utility of a physiologically based pharmacokinetic (PBPK) model, which incorporates model parameters representing key…”
Get full text

Mechanistic considerations for the use of monoclonal antibodies for cancer therapy by Glassman, Patrick M, Balthasar, Joseph P

“…Since the approval ofrituximab in 1997, monoclonal antibodies （mAbs） have become an increasingly important component of therapeutic regimens in oncology. The…”
Get full text

Physiologically-based modeling to predict the clinical behavior of monoclonal antibodies directed against lymphocyte antigens by Glassman, Patrick M, Balthasar, Joseph P

“…Many clinically approved and investigational monoclonal antibody (mAb)-based therapeutics are directed against proteins located in the systemic circulation,…”
Get full text